4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024992
CHIEF SCIENTIFIC OFFICER sold 51,145 shares at an average $28.11 ($1,437,585)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-10-08 | Sale 10b5-1 | −13,167 | $27.96 | $368,173 | 1,054,013 | I |
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-10-08 | Sale 10b5-1 | −100 | $28.51 | $2,851 | 1,053,913 | I |
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-10-09 | Sale 10b5-1 | −34,289 | $28.12 | $964,203 | 1,019,624 | I |
| Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | 2024-10-09 | Sale 10b5-1 | −3,589 | $28.52 | $102,358 | 1,016,035 | I |
| Open-market sales · 51,145 sh · avg $28.11 · $1,437,585 | |||||||
Loading xslF345X05/form4-10112024_121044.xml…